Atripla Evropska unija - poljščina - EMA (European Medicines Agency)

atripla

gilead sciences ireland uc - efawirenz, эмтрицитабин, tenofowir disoproxil fumarate - infekcje hiv - Środki przeciwwirusowe do użytku ogólnoustrojowego - atripla jest złożoną kombinacją efawirenzu, emtrycytabiny i fumaranu dizoproksylu tenofowiru. jest wskazany w leczeniu zakażenia ludzkim wirusem niedoboru odporności-wirus 1 (hiv-1) u dorosłych z supresją wirusologiczną do poziomu rna hiv-1 <50 kopii / ml w obecnej terapii złożonej przeciwretrowirusowej przez ponad trzy miesiące. pacjenci nie powinni mieć doświadczonych вирусологическая porażka na każdym do terapii antyretrowirusowej i musi być, wiadomo, nie żywił szczepów wirusa z mutacjami nadaniu znaczny opór każdego z trzech składników zawartych w Атриплы przed rozpoczęciem pierwszego schematu terapii antyretrowirusowej . demonstracja na rzecz Атрипла w pierwszej kolejności opiera się na 48-tygodniowe dane z badania klinicznego, w którym pacjenci ze stabilną вирусологическим walce na połączenie terapii antyretrowirusowej zmienia się na Атрипла. nie ma żadnych danych jest obecnie dostępna z badań klinicznych z atripla na leczenie-naiwny lub w znacznym stopniu wstępnie przetworzonych pacjentów. nie ma żadnych danych, aby utrzymać połączenie Атриплы i innych antyretrowirusowej agentów.

Atripla Evropska unija - portugalščina - EMA (European Medicines Agency)

atripla

gilead sciences ireland uc - o efavirenz, emtricitabina, tenofovir disoproxil fumarate - infecções por hiv - antivirais para uso sistêmico - atripla é uma combinação de dose fixa de efavirenz, emtricitabina e fumarato de tenofovir disoproxil. É indicado para o tratamento da infecção humano-imunodeficiência-vírus-1 (hiv-1) em adultos com supressão virológica para níveis de arn de hiv-1 <50 cópias / ml em sua combinação anti-retroviral atual por mais de três meses. os pacientes não devem ter sofrido uma falha virológica em qualquer terapia anti-retroviral prévia e devem ser conhecidos por não ter estirpes de vírus abrigadas com mutações que conferem resistência significativa a qualquer dos três componentes contidos em atripla antes do início do seu primeiro regime de tratamento anti-retroviral. a demonstração do benefício de atripla é principalmente com base em 48 semanas de dados a partir de um estudo clínico em pacientes com supressão virológica estável em terapêutica anti-retroviral combinada alterado para atripla. presentemente, não existem dados disponíveis de estudos clínicos com atripla em tratamento de ingênuo ou fortemente em pacientes pré-tratados. não há dados disponíveis para suportar a combinação de atripla com outros agentes anti-retrovirais.

ATRIPLA- efavirenz, emtricitabine, and tenofovir disoproxil fumarate tablet, film coated Združene države Amerike - angleščina - NLM (National Library of Medicine)

atripla- efavirenz, emtricitabine, and tenofovir disoproxil fumarate tablet, film coated

gilead sciences, llc - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - efavirenz 600 mg - atripla® is indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients weighing at least 40 kg. - atripla is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz, a component of atripla [see warnings and precautions (5.2)] . - atripla is contraindicated to be coadministered with voriconazole or elbasvir/grazoprevir [see drug interactions (7.3) and clinical pharmacology (12.3)]. antiretroviral pregnancy registry there is a pregnancy exposure registry that monitors pregnancy outcomes in adults and adolescents exposed to atripla during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at (800) 258-4263. risk summary there are retrospective case reports of neural tube defects in infants whose mothers were e

ATRIPLA- efavirenz, emtricitabine, and tenofovir disoproxil fumarate tablet, film coated Združene države Amerike - angleščina - NLM (National Library of Medicine)

atripla- efavirenz, emtricitabine, and tenofovir disoproxil fumarate tablet, film coated

remedyrepack inc. - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - efavirenz 600 mg - atripla ® is indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients weighing at least 40 kg. - atripla is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz, a component of atripla [see warnings and precautions (5.2)] . - atripla is contraindicated to be coadministered with voriconazole or elbasvir/grazoprevir [see drug interactions (7.3) and clinical pharmacology (12.3)]. antiretroviral pregnancy registry there is a pregnancy exposure registry that monitors pregnancy outcomes in adults and adolescents exposed to atripla during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at (8

Atripla Evropska unija - francoščina - EMA (European Medicines Agency)

atripla

gilead sciences ireland uc - l'éfavirenz, de l'emtricitabine, ténofovir disoproxil fumarate - infections au vih - antiviraux à usage systémique - atripla est une association fixe d'éfavirenz, d'emtricitabine et de fumarate de ténofovir disoproxil.. il est indiqué pour le traitement de l'homme de l'immunodéficience-virus-1 (vih-1) chez les adultes souffrant de la suppression virologique pour le vih-1 plasmatique < 50 copies/ml sur leur combinaison de la thérapie antirétrovirale pour plus de trois mois. les patients doivent n'a pas connu d'échec virologique sur tout avant la thérapie antirétrovirale et doit être connu pour ne pas avoir hébergé des souches de virus avec les mutations conférant une résistance importante à l'un des trois composants contenus dans atripla avant l'ouverture de leur premier traitement antirétroviral. la démonstration du bénéfice de l'atripla est principalement basée sur 48 semaines de données provenant d'une étude clinique dans laquelle les patients avec la stabilisation de la suppression virologique sur une combinaison de la thérapie antirétrovirale changé de atripla. pas de données sont actuellement disponibles à partir des études cliniques avec atripla en naïfs de traitement ou chez les patients lourdement prétraités. en l'absence de données disponibles à l'appui de la combinaison d'atripla et d'autres agents antirétroviraux.

ATRIPLA- efavirenz, emtricitabine, and tenofovir disoproxil fumarate tablet, film coated Združene države Amerike - angleščina - NLM (National Library of Medicine)

atripla- efavirenz, emtricitabine, and tenofovir disoproxil fumarate tablet, film coated

doh central pharmacy - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - efavirenz 600 mg - atripla® is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults. atripla is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz, a component of atripla. for some drugs, competition for cyp3a by efavirenz could result in inhibition of their metabolism and create the potential for serious and/or life-threatening adverse reactions (e.g., cardiac arrhythmias, prolonged sedation, or respiratory depression). drugs that are contraindicated with atripla are listed in table 1. pregnancy category d [see warnings and precautions (5.8)] the centers for disease control and prevention recommend that hiv-1 infected mothers not breast-feed their infants to avoid risking postnatal transmission of hiv-1. studies in rats have demonstrated that both efavirenz and tenofovir are secreted in milk. it is n

ATRIPLA- efavirenz, emtricitabine, and tenofovir disoproxil fumarate tablet, film coated Združene države Amerike - angleščina - NLM (National Library of Medicine)

atripla- efavirenz, emtricitabine, and tenofovir disoproxil fumarate tablet, film coated

physicians total care, inc. - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - efavirenz 600 mg - atripla® is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients 12 years of age and older. atripla is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz, a component of atripla. for some drugs, competition for cyp3a by efavirenz could result in inhibition of their metabolism and create the potential for serious and/or life-threatening adverse reactions (e.g., cardiac arrhythmias, prolonged sedation, or respiratory depression). drugs that are contraindicated with atripla are listed in table 1. pregnancy category d [see warnings and precautions (5.8)] antiretroviral pregnancy registry: to monitor fetal outcomes of pregnant women, an antiretroviral pregnancy registry has been established. physicians are encouraged to register patients who become pregnant by cal

Atripla Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

atripla

gilead sciences (nz) - efavirenz 600mg;  ;  ;  ; emtricitabine 200mg;  ;  ;  ; tenofovir disoproxil fumarate 300mg;  ;  ;   - film coated tablet - active: efavirenz 600mg       emtricitabine 200mg       tenofovir disoproxil fumarate 300mg       excipient: croscarmellose sodium hyprolose magnesium stearate microcrystalline cellulose opadry pink 85f94172 purified water sodium laurilsulfate - atripla is indicated for the treatment of hiv infected adults over the age of 18 years, alone or in combination with other antiretroviral agents.

ATRIPLA Izrael - angleščina - Ministry of Health

atripla

gilead sciences israel ltd - efavirenz; emtricitabine; tenofovir disoproxil as - film coated tablets - tenofovir disoproxil as 245 mg; emtricitabine 200 mg; efavirenz 600 mg - tenofovir disoproxil - tenofovir disoproxil - atripla is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults.

ATRIPLA ACCESS- efavirenz, emtricitabine, and tenofovir disoproxil fumarate tablet, film coated Združene države Amerike - angleščina - NLM (National Library of Medicine)

atripla access- efavirenz, emtricitabine, and tenofovir disoproxil fumarate tablet, film coated

gilead sciences, inc. - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - efavirenz 600 mg - atripla™ is indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients weighing at least 40 kg. - atripla is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz, a component of atripla [see warnings and precautions (5.2)]. - atripla is contraindicated to be coadministered with voriconazole or elbasvir/grazoprevir [see drug interactions (7.3) and clinical pharmacology (12.3)]. antiretroviral pregnancy registry there is a pregnancy exposure registry that monitors pregnancy outcomes in adults and adolescents exposed to atripla during pregnancy. healthcare providers are encouraged to register patients who become pregnant on the worldwide web at www.apregistry.com/. risk summary there are retrospective case reports of neural tube defects in infants whose mothers were exposed to efv-conta